

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ALEMBIC PHARMACEUTICALS LIMITED,
Petitioner,

v.

UCB PHARMA GMBH,
Patent Owner.

Case IPR2016-01596
Patent 6,858,650 B1

**PATENT OWNER MANDATORY NOTICE INFORMATION
UNDER 37 C.F.R. § 42.8**

IPR2016-01596

Patent 6,858,650 B1

A. Real Party in Interest

UCB Pharma GmbH (“UCB”), formerly known as Schwarz Pharma AG and organized and existing under the laws of Germany, holds title to U.S. Patent No. 6,858,650 (the “‘650 patent”) and is the real party-in-interest.

B. Related Matters

UCB and Pfizer Inc. (“Pfizer”), the exclusive licensee of the ‘650 patent, have sued Mylan Pharmaceuticals Inc. for infringement of the ‘650 patent in the following pending actions: *Pfizer, Inc. and UCB Pharma GmbH v. Mylan Pharmaceuticals, Inc.*, No. 1:15-cv-00079-GMS (D. Del.) and *Pfizer Inc. and UCB Pharma GmbH v. Mylan Pharmaceuticals Inc.*, Case No. 1:15-cv-00013-IMK (N.D.W.Va.).

The following action also involved the ‘650 patent: *Pfizer, Inc. and UCB Pharma GmbH v. Sandoz, Inc.*, et al., No. 1:13-cv-01110-GMS (D. Del.). Following trial before Judge Gregory Sleet in the District Court of Delaware in July 2015, judgment was entered that, *inter alia*, (1) the claims are not obvious under 35 U.S.C. § 103, (2) the claims are not anticipated under 35 U.S.C. § 102, and (3) the claims are not indefinite under 35 U.S.C. § 112. Defendants did not file a Notice of Appeal to the Federal Circuit. Defendants’ arguments at trial regarding obviousness included the assertion of, *inter alia*, Brynne (Petitioner’s Ex. 1007), Bundgaard (Petitioner’s Ex. 1012), Johansson (Petitioner’s Ex. 1005),

IPR2016-01596**Patent 6,858,650 B1**

and the Detrol Label (Petitioner's Ex. 1009). Defendants identified Postlind (Petitioner's Ex. 1010) in the Pretrial Order as a prior art reference potentially relevant for obviousness.

The Patent Trial and Appeal Board has instituted *Inter Partes* Review of Petitions filed by Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited, which are listed in the table below, relating to either the '650 patent or four other patents related to the '650 patent (U.S. Patent Nos. 7,384,980; 7,855,230; 7,985,772; and 8,338,478):

<u>Patent No.</u>	<u>Petitioners</u>	<u>Case No.</u>	<u>IPR Filing Date</u>	<u>Claims</u>
6,858,650	Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited	IPR2016-00510	January 28, 2016	1-5, 21-24
7,384,980	Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited	IPR2016-00512	January 28, 2016	1-16
7,855,230	Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited	IPR2016-00514	January 28, 2016	1-5

IPR2016-01596
Patent 6,858,650 B1

7,985,772	Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited	IPR2016-00517	January 28, 2016	1, 3, 4, 6-8
8,338,478	Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited	IPR2016-00516	January 28, 2016	1-3, 5-8, 10-12

Additionally, UCB understands that Torrent Pharmaceuticals Limited and Amerigen Pharmaceuticals Limited have each filed an *Inter Partes* Review Petition relating to the '650 patent, as well as Motions for Joinder of their petitions with IPR2016-00510:

<u>Patent No.</u>	<u>Petitioner</u>	<u>Case No.</u>	<u>IPR Filing Date</u>	<u>Claims</u>
6,858,650	Torrent Pharmaceuticals Limited	IPR2016-01636	August 18, 2016	1-5, 21-24
6,858,650	Amerigen Pharmaceuticals Limited	IPR2016-01665	August 22, 2016	1-5, 21-24

C. Lead and Back-up Counsel

Lead Counsel

Jeffrey Oelke, Reg. No. 37,409
White & Case LLP
1155 Avenue of the Americas

IPR2016-01596

Patent 6,858,650 B1

New York, NY 10036

(212) 819-8936

joelke@whitecase.com

Back-Up Counsel

James Trainor, Reg. No. 52,297

White & Case LLP

1155 Avenue of the Americas

New York, NY 10036

(212) 819-8580

jtrainor@whitecase.com

Robert Counihan, Reg. No. 61,382

White & Case LLP

1155 Avenue of the Americas

New York, NY 10036

(212) 819-8255

rcounihan@whitecase.com

D. Service Information

UCB may be served at its counsel, White & Case LLP, at the above-indicated email addresses.

E. Patent Owner Preliminary Response

Patent Owner reserves the right to file a preliminary response at a later date.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.